DMC Biotechnologies Closes $34M First Close of Series B Funding

DMC Biotechnologies, a Boulder, CO and Durham, NC-based biobased chemical company that makes products using microbial fermentation, completed the first close of its Series B fundraising, raising $34m (USD).

Backers included Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin.

Led by Matt Lipscomb, Ph.D., CEO & Co-Founder, DMC provides a bio-based chemical intermediate with primary applications in home care and human nutrition and has a deep pipeline of predictable, scalable, cost-competitive products, addressing sustainability challenges across a wide range of industries, including animal nutrition, human nutrition, personal and home care, and a broad range of chemical intermediates. 

The company’s proprietary technology simplifies biology and makes fermentation more predictable and efficient.